Hyeokjin Lim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hyeokjin Lim has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Eun La Kim
College of Pharmacy and Research Institute for Drug Development, Pusan National University, Busan 46241, Republic of Korea
1 shared publication - Eun Seo Jang
College of Pharmacy and Research Institute for Drug Development, Pusan National University, Busan 46241, Republic of Korea
1 shared publication - Hyeon-Jeong Hwang
College of Pharmacy and Research Institute for Drug Development, Pusan National University, Busan 46241, Republic of Korea
1 shared publication - Jae Sik Yu
Department of Integrative Biological Sciences and Industry, Sejong University, 209 Neungdong-ro, Gwangjin-gu, Seoul 05006, Republic of Korea
1 shared publication - Seonghwan Hwang
College of Pharmacy and Research Institute for Drug Development, Pusan National University, Busan 46241, Republic of Korea
1 shared publication - Seoung Rak Lee
College of Pharmacy and Research Institute for Drug Development, Pusan National University, Busan 46241, Republic of Korea
1 shared publication
Latest Publications
- Open Access
- 30 June 2025
- Published by MDPI AG in Marine Drugs
- Vol. 23 (7) , 275
Isolation and Characterization of Secondary Metabolites from Hydractinia-Associated Fungus, Penicillium brevicompactum MSW10-1, and Their Inhibitory Effects on Hepatic Lipogenesis
Marine organism-associated microbes are an important source of structurally diverse and biologically active secondary metabolites exhibiting antimicrobial, anticancer, and anti-inflammatory activities. In this study, we investigated Penicillium brevicompactum MSW10-1, isolated from Hydractinia echinata, a marine invertebrate adapted to extreme intertidal and subtidal environments with variable temperature, salinity, and oxygen conditions. Through a combination of LC/MS-guided chemical analysis and chromatographic purification, eight secondary metabolites were isolated, including brevicolactones A (1) and B (2). The absolute chemical structures of 1 and 2 were determined based on NMR spectroscopic experiments, HR-ESIMS data, and quantum chemical ECD calculations. The isolated compounds (1–8) were evaluated for their ability to inhibit hepatic lipogenesis, a key process in lipid metabolism that is dysregulated in metabolic-dysfunction-associated steatotic liver disease. Furthermore, the inhibitory effects of the isolated compounds on lipid accumulation were further evaluated in primary mouse hepatocytes, using Oil Red O staining. These findings suggested that the isolated compounds may serve as promising candidates for the treatment of metabolic liver diseases associated with lipid dysregulation.
- 30 June 2025
- Published by MDPI AG in Marine Drugs
- Vol. 23 (7) , 275
Open AccessIsolation and Characterization of Secondary Metabolites from Hydractinia-Associated Fungus, Penicillium brevicompactum MSW10-1, and Their Inhibitory Effects on Hepatic Lipogenesis
Marine organism-associated microbes are an important source of structurally diverse and biologically active secondary metabolites exhibiting antimicrobial, anticancer, and anti-inflammatory activities. In this study, we investigated Penicillium brevicompactum MSW10-1, isolated from Hydractinia echinata, a marine invertebrate adapted to extreme intertidal and subtidal environments with variable temperature, salinity, and oxygen conditions. Through a combination of LC/MS-guided chemical analysis and chromatographic purification, eight secondary metabolites were isolated, including brevicolactones A (1) and B (2). The absolute chemical structures of 1 and 2 were determined based on NMR spectroscopic experiments, HR-ESIMS data, and quantum chemical ECD calculations. The isolated compounds (1–8) were evaluated for their ability to inhibit hepatic lipogenesis, a key process in lipid metabolism that is dysregulated in metabolic-dysfunction-associated steatotic liver disease. Furthermore, the inhibitory effects of the isolated compounds on lipid accumulation were further evaluated in primary mouse hepatocytes, using Oil Red O staining. These findings suggested that the isolated compounds may serve as promising candidates for the treatment of metabolic liver diseases associated with lipid dysregulation.